{"url_path":"/sec/urgn/8-k/2026-06-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **         **Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1668243/0001437749-26-019102-index.html","accession_number":"0001437749-26-019102","cik":"0001668243","ticker":"URGN","issuer_name":"UroGen Pharma Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1668243/0001437749-26-019102-index.html","primary_entity_key":"0001668243","primary_entity_name":"UroGen Pharma Ltd."},"word_count":246,"has_tables":true,"body_markdown":"**Item 8.01**         **Other Events.**\n\n \n\nOn June 2, 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. (collectively, “the Company”) issued a press release announcing that the Company entered into a settlement and license agreement (the “Agreement”) with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”) that resolves the patent litigation between the parties related to *Jelmyto*® (mitomycin) for pyelocalyceal solution.\n\n \n\nThe patent litigation resulted from Teva’s submission of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (“FDA”) seeking approval to manufacture, use or sell a generic version of *Jelmyto* in the United States prior to the expiration of relevant Company patents. Under the terms of the Agreement, the Company will grant Teva a non-exclusive license to sell Teva’s generic version of *Jelmyto* beginning on September 15, 2030, if approved by the FDA, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing patent litigation between the Company and Teva regarding *Jelmyto* patents pending in the U.S. District Court for the District of Delaware.\n\n \n\nThe Agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: June 2, 2026\n\n**UROGEN PHARMA LTD.**\n\n \n\n \n \n \n \n\n \n \n \n \n\n \n\nBy:\n\n/s/ Chris Degnan\n\n \n\n \n \n\nChris Degnan\n\n \n\n \n \n\nChief Financial Officer"}